Results 91 to 100 of about 114,228 (331)
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu +3 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 927-941, April 2025.Abstract Socio‐economic status (SES) has been associated with incident and prevalent heart failure (HF), as well as its morbidity and mortality. However, the precise nature of the relationship between SES and HF remains unclear due to inconsistent data. This study aims to provide a comprehensive assessment and data synthesis of the relationship between
Abdul Shakoor +8 more
wiley +1 more source
Arterial hypertension and coronary heart disease: the place of angiotensin II receptor antagonists
Кардиоваскулярная терапия и профилактика, 2012 The paper considers arterial hypertension and coronary heart disease as pathologies which share multiple pathogenetic mechanisms. The role of angiotensin II receptor antagonists (ARA) in the effective treatment of these diseases and in prevention of ...
E. O. Taratukhin
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen +4 more
wiley +1 more source
Participação de receptores angiotensinérgicos na ingestão de água induzida pela injeção intracerebroventricular de serotonina e angiotensina em pombos (Columba livia) / [PDF]
, 1999 Dissertação (Mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências ...
Brun, Sandra Regina Martini
core
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
A role for the brain RAS in Alzheimer's and Parkinson's diseases
Frontiers in Endocrinology, 2013 The brain renin-angiotensin system (RAS) has available the necessary functional components to produce the active ligands angiotensins II, III, IV, angiotensin (1-7), and angiotensin (3-7).
John William Wright +2 more
doaj +1 more source
[Antagonists of angiotensin II receptor].
Postepy higieny i medycyny doswiadczalnej, 1996 Angiotensin II exerts its activity by binding to its receptors. The two main types AII receptors, properties of Losartan (first orally active, specific, competitive, nonpeptide AII receptor antagonist) and its clinical applications are described.
D, Karasek, M, Adamski, W, Grzeszczak
openaire +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou +7 more
wiley +1 more source